

COMMONWEALTH OF AUSTRALIA
The Patents Act 1952
CONVENTION APPLICATION FOR A PATENT

623800

We, DR KARL THOMAE GMBH, a German body corporate of D-7950 Biberach an der Riss, West Germany, hereby apply for the grant of a Patent for an invention entitled "NEW 1,3-OXAZINES" which is described in the accompanying complete specification.

This application is a Convention application and is based on the Application Numbered P 3926898.5 for a patent or similar protection made in Germany on 16 August 1989.


Our address for service is care of CALLINAN LAWRIE, Patent Attorneys, of 278 High Street, Kew, 3101, Victoria, Australia.

D A T E D this 16 day of August 1990.

DR KARL THOMAE GMBH

By their Patent Attorneys:

CALLINAN LAWRIE



To: The Commissioner of Patents.

COMMONWEALTH OF AUSTRALIA

Patents Act 1952

Declaration in Support of an Application for Patent

In support of the Convention application made for a patent for an invention entitled "NEW 1,3-OXAZINES".

I, KEITH W. CALLINAN, of 278 High Street, Kew, 3101, Victoria, Australia, do solemnly and sincerely declare as follows:-

1. I am authorised by DR KARL THOMAE GmbH the applicant for the patent to make this declaration on its behalf.

2. The basic application as defined by Section 141 of the Act is -

<u>Filing Date</u>	<u>Country</u>	<u>Applicant</u>
16 August 1989	Germany	Dr Karl Thomae GmbH

3. The basic application referred to in this Declaration was the first application made in a Convention country in respect of the invention the subject of the application.

4. Helmut BALLHAUSE of Fohrenweg 6, D-7950 Biberach 1, West Germany; Gunther ENGELHARDT of Unterer Buhl 18, D-7950 Biberach 1, West Germany; Claus Adolf LANDGRAF of Schubertweg 3, D-7950 Biberach 1, West Germany; Norbert MAYER of Friedrich-Ebert-Strasse 66, D-7950 Biberach 1, West Germany; Willy ROTH of Amriswilstrasse 7, D-7950 Biberach 1, West Germany; Kurt SCHUMACHER of Friedrich Profit Strasse 9, D-6720 Speyer, West Germany and Axel PROX of Schillerstrasse 24, D-7951 Warthausen, West Germany are the actual inventors of the invention and the facts upon which the applicant is entitled to make the application are as follows:-

The applicant would, if a patent were to be granted upon an application made by Helmut Ballhause, Gunther Engelhardt, Claus Adolf Landgraf, Norbert Mayer, Willy Roth, and/or Axel Prox, be entitled to have the patent assigned to it; and the applicant is the assignee of the invention from Kurt Schumacher.


Declared at Kew this 16 day of August 1990.

Signed: 

(12) PATENT ABRIDGMENT (11) Document No. AU-B-61037/90
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 623800

- (54) Title
NEW 1,3-OXAZINES
- (51)⁵ International Patent Classification(s)
C07D 265/06 A61K 031/535
- (21) Application No. : 61037/90 (22) Application Date : 16.08.90
- (30) Priority Data
- (31) Number (32) Date (33) Country
3926898 16.08.89 DE FEDERAL REPUBLIC OF GERMANY
- (43) Publication Date : 21.02.91
- (44) Publication Date of Accepted Application : 21.05.92
- (71) Applicant(s)
DR KARL THOMAE GMBH
- (72) Inventor(s)
HELMUT BALLHAUSE; GUNTHER ENGELHARDT; CLAUS ADOLF LANDGRAF; NORBERT MAYER;
WILLY ROTH; KURT SCHUMACHER; AXEL PROX
- (74) Attorney or Agent
CALLINAN LAWRIE , Private Bag 7, KEW VIC 3101
- (56) Prior Art Documents
AU 557690 77957/81 C07D 265/06
- (57) Claim

1. Compounds of general formula I



wherein R₁ represents a hydrogen or halogen atom;

R₂ represents a C₁₋₃alkyl group; and

R₃ and R₄, which may be identical or different, each represents a C₁₋₃alkyl group;

and acid addition salts thereof.

(11) AU-B-61037/90
(10) 623800

-2-

10. A method of treatment of a human or non-human animal body for a cough of the respiratory tract said method comprising administering to said body a compound of formula I as claimed in any one of claims 1 to 5 or a physiologically acceptable acid addition salt thereof.

11. A method of treatment of a human or non-human animal body for whooping cough, irritable and spasmodic coughing, said method comprising administering to said body a compound of formula I as claimed in any one of claims 1 to 5 or a physiologically acceptable acid addition salt thereof.

COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE

Short Title:

Int. Cl:

Application Number:
Lodged:

Complete Specification - Lodged:
Accepted:
Lapsed:
Published:

Priority:

Related Art:

TO BE COMPLETED BY APPLICANT

Name of Applicant: DR KARL THOMAE GMBH

Address of Applicant: a German Body Corporate of D-7950 Biberach an der Riss, West Germany

Actual Inventors: Helmut BALLHAUSE; Gunther ENGELHARDT; Claus Adolf LANDGRAF;
Norbert MAYER; Willy ROTH; Kurt SCHUMACHER and Axel PROX

Address for Service: CALLINAN LAWRIE, 278 High Street, Kew, 3101, Victoria, Australia

Complete Specification for the invention entitled: "NEW 1,3-OXAZINES"


The following statement is a full description of this invention, including the best method of performing it known to me:-

File No. 55 817b.520


New 1,3-Oxazines

This invention relates to 1,3-oxazines, pharmaceutical compositions containing them and methods for their preparation.

One of the best known antitussives is the morphine derivative "codeine" which has the formula



Also, German Patent No. P1146068 describes base-substituted carbinols of general formula




wherein R_1 to R_5 represent lower alkyl groups and R_3 may be a hydrogen or a p-halogen atom and which may be used

as antitussives. One of these compounds, 1-p-chloro-2,3-dimethyl-4-dimethylaminobutanol, has been on the market for some years as a commercial preparation of the Firm Dr Karl Thomae GmbH under the name "Silomat". The substance has the INN generic name "Clobutinol".

It is an object of the present invention to provide new compounds which have an antitussive effect but do not have the known unpleasant side affects of codeine.

Viewed from one aspect, the invention provides new 1,3-oxazines of general Formula I



wherein

R_1 represents a hydrogen or halogen atom;

R_2 represents a C_{1-3} alkyl group; and

R_3 and R_4 , which may be identical or different, each represents a C_{1-3} alkyl group; and

the acid addition salts thereof with organic or inorganic acids.


It will be appreciated that for pharmaceutical use the acid addition salts referred to above will be physiologically acceptable acid addition salts but other

acid addition salts may find use, for example, as intermediates in the preparation of compounds of Formula I.

Preferred compounds of general Formula I above are those wherein R_1 is a halogen atom in the para position.

Particularly preferred compounds are those wherein R_1 is a chlorine atom, preferably p-chlorine, and R_2 to R_4 , which may be identical or different, each represents a methyl or ethyl group.


Viewed from another aspect, the invention provides a process for preparing these new compounds, characterised in that a compound of general Formula II



or an acid addition salt thereof is reacted with an aqueous formaldehyde solution, expediently at temperatures between 20°C and the boiling temperature of the solution, but preferably at ambient temperature. The compound of general Formula I or, preferably an acid addition salt thereof, is formed initially and isolated by methods known per se. If desired a free base is converted into an acid addition salt or an acid addition salt is converted into a free base by methods known per se.


The compounds of general Formula II may be prepared for example by the following methods:

a) Mono-de-N-alkylation of a compound of general Formula III



or an acid addition salt thereof, where R_1 to R_4 are defined as hereinbefore and R_2' represents an alkyl group and is advantageously identical to R_2 , or

b) Removal of the protecting group Pg from a compound of general Formula IV



or an acid addition salt thereof.

The mono-de-N-alkylation according to process a) may be carried out by methods known per se, e.g. by reacting with diethylazodicarboxylate in a non-polar solvent such as toluene at a temperature up to the boiling temperature of the mixture and hydrolysing the resulting products, preferably with the use of ammonium chloride solution in a polar solvent such as methanol/water at a temperature up to the boiling temperature of the mixture.


Compounds of general Formula III are known from the literature, e.g. from German Patent applications P1146068 and P1153380.




Process b) may be carried out by methods known per se, depending on the identity of the protecting group.

The protecting group is preferably the t-butyloxycarbonyl group (Boc) which can be split off by the use of trifluoroacetic acid.

The compounds of general Formula IV may be prepared by methods known per se. Preferably, these intermediate products are produced using compounds of general Formula III as starting materials according to the following reaction plan:

Compounds of Formula III





Compounds of Formula IV

In the above reaction sequence a compound of Formula III is reacted with acetyl chloride in an inert solvent, e.g. toluene, at a temperature up to the boiling temperature. Compound V or a hydrochloride salt thereof may be isolated by methods known per se and then stirred with alpha-chloroethyl chloroformate in 1,2-dichloroethane or another suitable organic solvent at a temperature up to the boiling temperature of the mixture. Compound VI can be isolated from this mixture using further processing methods known per se. The resulting compound is then heated to boiling in

methanol or another inert solvent. The secondary amine VII thus produced is then precipitated as the hydrochloride, which is isolated and then purified and dried by known methods. Compound VII is then converted into protected amino derivatives by methods known per se. Preferably, this is carried out with Di-t-butyl-di-carbonate in an organic solvent such as dioxane, for example, in the presence of an organic base such as triethylamine at a temperature from 20°C to the boiling temperature of the mixture, preferably at ambient temperature.

If the compounds of general Formula I obtained have not already been prepared as acid addition salts, they may be converted into the physiologically acceptable acid addition salts with organic or inorganic acids by known methods, e.g. by reacting an alcoholic solution of the base with an equimolar quantity of the corresponding acid in ether. Acids which have proved suitable include hydrochloric, hydrobromic, sulphuric, phosphoric, lactic, citric, tartaric and maleic acids.

The 1,3-oxazines of Formula I are racemates, which can, if desired, be split into their optically active antipodes in the usual way, e.g. with optically active acids or by fractional crystallisation. The compounds according to the invention may be prepared, for example, from the active antipodes of the compounds III, whilst the starting materials of Formula III, for example, may be resolved into their optically active antipodes, e.g. by racemate separation by liquid chromatography and processes a) or b) may be carried out. The intermediate products V to VIII may be treated in the same way if they occur as racemates. The optical purity of the starting or intermediate substances of Formula III, for example, and of the antipodes of the compounds of Formula I claimed may be

demonstrated by liquid chromatography on a chiral column (see Figs 1 to 5).

For medical use the compounds according to the invention may be incorporated, with the aid of conventional galenic excipients such as lactose, manitol, corn starch, methyl cellulose, hydroxyethyl cellulose, polyethylene oxide, highly dispersed aluminium oxide, magnesium-aluminium silicate, magnesium oxide, magnesium stearate, sodium lauryl sulphate, sodium citrate, tartaric acid, sodium pyrosulphite, dioctylsodiumsulfosuccinate, sodium salt of methyl p-hydroxybenzoate, sodium salt of propyl p-hydroxybenzoate, sodium saccharin, flavourings and antifoamers into conventional galenic preparations such as tablets, film-coated tablets, oblong tablets, coated tablets or capsules and the delayed release forms thereof, ampoules, dry ampoules, dry granules or dry elixirs.

The antitussive activity of the compound 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3, 4, 5, 6-tetrahydro-oxazine (1,3)-hydrochloride was tested as follows:

33 male and female cats with a body weight of 3.4 to 4.5 kg were anaesthetised with pentobarbital-Na (45 mg/kg as an initial bolus i.p. and then, spread throughout the experiment, several times as required, 7.5 or 15 mg/kg i.v.). Care was taken to keep the animals at about stage 1 to 2 (Guedel) of the tolerance stage.

Coughing fits were provoked mechanically by the insertion of a plastic catheter with a rounded tip, diameter about 1.5 mm, into the trachea as far as the bifurcation. At each instance of irritation,

stimulation was carried out three times, separated by intervals of about 30 seconds. The coughing fits were always provoked 5, 25 and 45 minutes after administration of the test substance or vehicle.

The test substance was administered as a solution in 0.9% NaCl solution through a catheter in the V. femoralis. The injected volume was not more than 0.5 ml/kg. Before administration of the substance, the effect of the vehicle was tested on each animal.

In order to evaluate the cough-suppressing effect, the number of stimuli which did not result in coughing fits were correlated to the total number thereof at each time after administration of the substance and the percentage inhibition was thus calculated (see Table 1).

Table 1

Percentage inhibition of coughing, MW $\pm$ SE
after minutes

Substance	Dosage					
	mg/kg	i.v. n	5	25	45	
Control	-	33	6.1 $\pm$ 3.4	5.1 $\pm$ 3.2	7.1 $\pm$ 3.3	
Active substance	0.5	5	26.7 $\pm$ 8.5	16.7 $\pm$ 10.5	23.3 $\pm$ 10.0	
	0.705	5	23.3 $\pm$ 6.7	13.3 $\pm$ 6.2	13.3 $\pm$ 3.3	
	1.0	5	33.3 $\pm$ 18.3	40.0 $\pm$ 16.3	36.7 $\pm$ 3.3	
	1.41	5	63.3 $\pm$ 13.3	53.3 $\pm$ 16.2	50.0 $\pm$ 18.3	
	2.0	5	33.3 $\pm$ 17.5	53.3 $\pm$ 14.3	36.7 $\pm$ 17.0	
	2.82	5	36.7 $\pm$ 14.3	43.3 $\pm$ 13.5	40.0 $\pm$ 11.3	
	4.0	5	60.0 $\pm$ 11.3	63.3 $\pm$ 13.3	46.7 $\pm$ 9.7	
	5.64	5	70.0 $\pm$ 20.0	70.0 $\pm$ 20.0	63.3 $\pm$ 17.0	
	8.0	3	44.4 $\pm$ 29.4	50.0 $\pm$ 25.5	44.4 $\pm$ 20.0	

where n represents the number of animals tested.

By linear regression analysis and linear covariance analysis, the ED₅₀ value (the value which gave a 50% reduction in the number of coughs) was determined after parallel adjustment (Table 2).

Table 2

Minutes after administration of substance	ED ₅₀ mg/kg i.v. after parallel adjustment
---	--

5	2.6
25	2.4
45	3.2

The substance, administered intravenously in doses of 0.5 to 8 mg/kg, had the effect of reducing the number of mechanically provoked coughs. The cough-suppressing effect was observed from the lowest administered dose upwards, at every testing time.

The new compounds of general Formula I according to the invention and the physiologically acceptable acid addition salts thereof are suitable, in view of the above mentioned pharmacological properties thereof, as antitussives, particularly for treating coughs in the respiratory tract, whooping cough, irritable and spasmodic coughing.

Thus, viewed from a further aspect, the invention provides a method of treatment of a human or non-human animal body for a cough of the respiratory tract said method comprising administering to said body a compound of general formula I or a physiologically acceptable salt thereof.

Viewed from yet a further aspect, the invention provides a method of treatment of a human or non-human animal body for whooping cough, irritable and spasmodic coughing, said method comprising administering to said body a compound of general formula I or a physiologically acceptable salt thereof.

Viewed from a still further aspect, the invention provides the use of a compound of general formula I for the preparation of a pharmaceutical composition for treating coughs.

The dosage required to achieve the effect is conveniently 0.1 to 4.0 mg/kg, preferably 0.3 to 1.5 mg/kg, 2 to 4 times a day.

Example 1

6-(p-chloro-benzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine(1,3)-hydrochloride

4.0g of 1-(p-chloro-phenyl)-2-hydroxy-2,3-dimethyl-4-methylaminobutane hydrochloride were dissolved in 10 ml of water and 10 ml of approximately 36% formaldehyde solution were added. After standing for 12 hours at ambient temperature the mixture was made alkaline with conc. ammonia whilst being cooled and the base fractions were extracted with ether. After the ether phase had been dried over sodium sulphate the filtrate was concentrated by evaporation and the oily residue was taken up in a little methanol. The methanolic solution was adjusted to a pH of about 5 with ethereal hydrochloric acid and sufficient ether was added to precipitate the hydrochloride formed. The solution was heated to boiling with ethyl acetate, with partial evaporation of ether and methanol, until the hydrochloride was precipitated. The hydrochloride was suction filtered, decocted with ethyl acetate, filtered and dried.

Mp $\approx$ 198-200°C, yield: 3.3g.

If the enantiomers of nor-clobutinol are treated analogously, the enantiomers of the 1,3-oxazine claimed are obtained having the following rotary values:

From (+)-clobutinol $\rightarrow$ (+)-nor-clobutinol $\rightarrow$
(-)-1,3-oxazine-HCl: $[\alpha]_D^{20} = -16.83^\circ$ (c=0.303;
0(589) 1 dm; pure ethanol)

Melting point: 197-199°C

From (-)-clobutinol -> (-)-nor-clobutinol ->
(+)-oxazine-HCl (1,3): $[\alpha]_{D(589)}^{20} = +16.6^\circ$ (c=0.301;
1 dm; pure ethanol)

Melting point: 197-199°C

Example 2

Tablets containing 5.0 mg of 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine-(1,3)-hydrochloride

Composition:

Active substance	5.0 mg
Lactose	148.0 mg
Potato starch	65.0 mg
Magnesium stearate	2.0 mg
	220.0 mg

Method of preparation:

A 10% mucilage is prepared from potato starch by heating. The active substance, lactose and remaining potato starch are mixed together and granulated with the mucilate through a screen with a mesh size of 1.5 mm. The granules are dried at 45°C, rubbed through the same screen again, mixed with magnesium stearate and compressed into tablets.

Example 3

Ampoules containing 10 mg of 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine (1,3)-hydrochloride

Composition:

Active substance	10.0 mg
Sodium chloride	8.0 mg
Distilled water	<u>ad</u> 1 ml

Method of preparation:

The active substance and sodium chloride are dissolved in distilled water and topped up to give the required volume. The solution is sterile filtered and transferred into 1 ml ampoules.

Sterilisation: 20 minutes at 120°C.

Example 4

Drops containing 0.5 mg of 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine (1,3)-hydrochloride per 100.0 ml

Composition:

Methyl p-hydroxybenzoate	0.035 g
Propyl p-hydroxybenzoate	0.015 g
Aniseed oil	0.05 g
Menthol	0.06 g
Pure ethanol	10.0 g
Active substance	0.5 g
Sodium cyclamate	1.0 g
Glycerol	15.0 g
Distilled water	<u>ad</u> 100.0 ml

Method of preparation:

The active substance and sodium cyclamate are dissolved in about 70 ml of water and glycerol is added. The

p-hydroxybenzoates, aniseed oil and menthol are dissolved in ethanol and this solution is added to the aqueous solution with stirring. Finally it is topped up to 100 ml with water and filtered to remove any suspended particles.

Reference Example 1

1-(p-chlorophenyl)-2-hydroxy-2,3-dimethyl-4-methylamino-butane hydrochloride

26.5 g of clobutinol base are heated to boiling for four hours with 21.0 g of diethyl azodicarboxylate (1.1 molar to clobutinol) in 200 ml of dry toluene. After the toluene has evaporated off in vacuo the residue is hydrolysed for four hours at boiling temperature with 200 ml of methanol and 200 ml of saturated ammonium chloride solution.

The mixture is concentrated by evaporation and the resulting semi-solid residue is mixed with 100 ml of a mixture of equal parts of concentrated hydrochloric acid and water. After suction filtering through a broad filter and re-filtering of the filtrate, the latter is made alkaline with 40% sodium hydroxide solution and ice, and the basic fractions are extracted with ether. The ether phase is separated off and dried over sodium sulphate, then stirred with activated charcoal, filtered and concentrated by evaporation. The concentrated residue is purified by column chromatography on silica gel (0.05 to 0.2 mm) using methylene chloride - methanol - ammonia (940+60+4) to (900+100+6) as eluant. The polar fractions containing the desired nor-clobutinol are combined and the solvent is distilled off. The crude base is converted into the hydrochloride. The basic residue is taken up in a little methanol and neutralised by ethereal hydrochloric acid. The

hydrochloride of the desired compound is precipitated. The precipitation is completed by the addition of more ether.

Melting point 182-183°C, about 4.0 g.

Starting from (+) or (-) clobutinol, the corresponding enantiomer of nor-clobutinol is obtained.

Reference Example 2

1-(chlorophenyl)-2-hydroxy-2,3-dimethyl-4-methylamino-butane hydrochloride

A. O-acetyl-clobutinol

8.5 ml of acetyl chloride in 20 ml of toluene are added drop wise at 80°C oil bath temperature to 30.0 g of clobutinol base in 150 ml of toluene and the reaction mixture is then heated to boiling for 2 hours. The desired hydrochloride rapidly begins to be precipitated and after cooling of the mixture the hydrochloride is suction filtered, rinsed with ether and dried.

B. N-(alpha-chloroethyl carbamate) of O-acetyl-nor-clobutinol

16.0 g of O-acetyl-clobutinol base (step A) in 100 ml of 1,2-dichloroethane are heated to boiling for 3 hours with 11.0 g of alpha-chloroethyl-chloroformate in 50 ml of 1,2-dichloroethane. The mixture is then extracted with 1N hydrochloric acid and ice, the organic phase is separated off and extracted under neutral conditions with potassium bicarbonate solution (mixed with ice). The organic layer is separated off, dried over sodium sulphate and the solution is filtered off and evaporated to dryness.

The residue is further processed without any further purification.

C. O-acetyl-nor-clobutinol hydrochloride

The oily residue of the above compound from step B is taken up in 50 ml of methanol and refluxed for 2 hours. The desired hydrochloride starts to be precipitated immediately. Some of the methanol is then distilled off, the mixture is cooled and the crystals are suction filtered. About 10.0 g of hydrochloride are obtained after rinsing with ethyl acetate and drying.
MP=185-188°C.

D. O-acetyl-N-Boc-nor-clobutinol

12.8 g of the product of step C are stirred in 500 ml of dioxane together with 10.0 g of di-t-butyl-di-carbonate and 4.0 g of triethylamine for 12 hours at ambient temperature. Then the suspension is suction filtered and the filtrate is concentrated by evaporation. The residue is further processed without any more purification.

E. N-Boc-nor-clobutinol

The oily residue from step D is refluxed with 50 ml of 1N-sodium hydroxide solution and 100 ml of methanol for 3 hours. Then the methanol is evaporated off in vacuo and the alkaline aqueous suspension is extracted with ether. The ether phase is separated off, dried over sodium sulphate and concentrated by evaporation after it has been filtered. The initially oily residue becomes solid after some time. The solid residue is powdered and used directly for reacting with trifluoroacetic acid.

F. Nor-clobutinol

12.0 g of the above Boc compound from step E are dissolved in 40 ml of ice-cooled trifluoroacetic acid. The reaction solution is left to stand for 30 minutes whilst cooling with ice and for 2 hours at ambient temperature. Then the majority of the trifluoroacetic acid is distilled off at 30°C, the residue is taken up in water and ice and the non-basic fractions are extracted with ether. The aqueous phase is separated off, made alkaline with 40% sodium hydroxide solution whilst cooling with ice, and extracted with methylene chloride. The organic phase is separated off and distilled off and the residue is converted into the hydrochloride. To do this, the oily base is dissolved in a little methanol and ethereal hydrochloric acid is added until the pH is 5. The hydrochloride is then precipitated. Precipitation is completed by the addition of more ether. After suction filtering, the hydrochloride is washed with ethyl acetate. After drying the salt has a melting point of 182-184°C, yield 8.0 g.

Reference Example 3

Analytical demonstration of the optical unity of the I and II enantiomers

(A) The racemate ($\pm$) 1-p-chlorophenyl-2,3-dimethyl-4-dimethylaminobutan-2-ol is added to an LKB column and eluted with propanol-2 (0.5%) and phosphate buffer, pH 6. As shown in Figure 1, the (-) enantiomer was obtained after 9.25 minutes and the (+) enantiomer after 12.25 minutes.

(B) The racemate ($\pm$) 6-(p-chlorobenzyl)-3,4,5-trimethyl-2H-3,4,5,6-tetrahydro-oxazine(1,3) was added

to a chiracel OD column and eluted with 495 ml of hexane and 5 ml of propanol-2. As shown in Figure 2, the (-) enantiomer was obtained after 11.89 minutes and the (+) enantiomer after 13.22 minutes.

(C) The (+) and (-) enantiomers of the compound 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine(1,3) were prepared by stereo specific methods using the corresponding (+) and (-) clobutinol as starting material. Figures 3 and 4 show the results of the chromatographic analysis of the corresponding products on a chiracel OD column. The (+) and (-) enantiomers of the oxazine were mixed together and also eluted; the results are shown in Figure 5.

Reference Example 4

Test of binding to the opiate receptor

In each experiment, two male rats (about 200 g) were killed by a blow to the neck. Their brains were removed and the brain stem together with the medulla was dissected out and weighed. These tissues were homogenised in 30 ml of 50mM Tris HCl buffer, pH 7.4, using a Potter homogenizer. The resulting homogenised material was centrifuged at 18000xg for 15 minutes.

By subsequent resuspension and centrifugation the pellets were washed twice. The resulting pellets were suspended with 200 times their weight of Tris HCl buffer, pH 7.4. In order to correlate the binding, 1 ml of this preparation was incubated with 0.5 mM 3H-diprenorphine (38.9 Ci/nmol Amersham), which is a non-selective ligand for the opiate receptors, and the test compound was incubated at varying concentrations in an ice bath.

Incubation was ended after 3 hours and the mixture was rapidly filtered in an "Ismatec Filter-Prep 101 sample processor" using a Whatman GF/B glass wool filter.


The filtrate was rinsed 3 times with 3 ml of carbonised buffer and transferred into small ampulles containing 4 ml of Instasel and extracted overnight. Then the radioactivity was measured. All the measurements were carried out 3 times. Any bound radioactivity found in the presence of 100 nM naloxone was regarded as non-specific binding.

Results

The radio-labelled opiate-agnostic compound 3H-diprenorphine binds specifically and reversibly to the opiate receptors of the preparations. According to Scatchard analysis, a K_D value of 0.51 nM was calculated in a saturation test. The specific binding of 0.5 nM 3H-diprenorphine would be inhibited by naloxone with an IC_{50} value of 3nM. By contrast to this finding, the test compound shows no inhibition of 3H-diprenorphine up to 100 μ M.

The claims defining the invention are as follows:-

1. Compounds of general formula I



wherein R_1 represents a hydrogen or halogen atom;

R_2 represents a C_{1-3} alkyl group; and

R_3 and R_4 , which may be identical or different, each represents a C_{1-3} alkyl group;

and acid addition salts thereof.

2. Compounds according to claim 1, wherein R_1 represents a halogen atom in the p position.


3. Compounds according to claim 1 or 2, wherein R_1 represents a chlorine atom and R_2 , R_3 and R_4 , which may be identical or different, each represents a methyl or ethyl group.

4. 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine(1,3) or the physiologically acceptable acid addition salts thereof with organic or inorganic acids.

5. 6-(p-chlorobenzyl)-3,5,6-trimethyl-2H-3,4,5,6-tetrahydro-oxazine(1,3) hydrochloride.

6. Pharmaceutical composition comprising a compound of formula I as claimed in any one of claims 1 to 5 or a physiologically acceptable acid addition salt thereof together with one or more inert carriers and/or diluents.

7. Process for preparing a compound according to any one of claims 1 to 5, characterised in that a compound of general Formula II



wherein R_1 , R_2 , R_3 and R_4 are defined as in claim 1, or an acid addition salt thereof, is reacted with a formaldehyde solution and the resulting compound according to Formula I of claim 1 is isolated in the form of an acid addition salt or free base thereof and if desired a free base is converted into an acid addition salt or an acid addition salt is converted into a free base.

8. A process as claimed in claim 8 wherein the reaction temperature is from 20°C to the boiling temperature of the solution.

9. A process as claimed in either of claims 8 and 9 wherein said reaction is performed at ambient temperature.

10. A method of treatment of a human or non-human animal body for a cough of the respiratory tract said method comprising administering to said body a compound of formula I as claimed in any one of claims 1 to 5 or a physiologically acceptable acid addition salt thereof.



11. A method of treatment of a human or non-human animal body for whooping cough, irritable and spasmodic coughing, said method comprising administering to said body a compound of formula I as claimed in any one of claims 1 to 5 or a physiologically acceptable acid addition salt thereof.

12. A compound of formula I as herein disclosed in any one of the Examples.

13. A process for the preparation of a compound as defined in claim 1 or an acid addition salt thereof, substantially as herein disclosed in any one of the Examples.

14. Compounds of formula I as defined in claim 1 and acid addition salts thereof whenever prepared by a process as claimed in any one of claims 8 to 10.

DATED this 27th day of February 1992.

DR KARL THOMAE GmbH

By Their Patent Attorneys:

CALLINAN LAWRIE

Michael J. Houlihan.




16 8 90 81037

FIG. 1

LIQUID CHROMATOGRAPHIC RACEMATE RESOLUTION

(±)-CLOBUTINOL




COLUMN: ENANTIOPAC LKB

ELUANT: PHOSPHATE BUFFER $P_H=6$ AND PROPANOL-2 (0.5%)

FIG. 2

(±) 6-(p-CHLOROBENZYL)-3,5,6-TRIMETHYL-2H-3,4,5,6 TETRAHYDRO-
OXAZINE (1,3)



COLUMN: CHIRALCEL OD

ELUANT: 495ml HEXANE AND 5ml PROPANOL-2

(-) - 6-(p-CHLOROBENZYL)-3,5,6-TRIMETHYL-
2H-3,4,5,6-TETRAHYDRO OXAZINE (1,3)




FIG. 3

(+) - 6-(p-CHLOROBENZYL)-3,5,6-TRIMETHYL-
2H-3,4,5,6-TETRAHYDRO- OXAZINE (1,3)





FIG. 4

FIG. 5

(+)- AND (-)-ENANTIOMERS OF FIGS 3 AND 4



LC CONDITIONS AS IN FIG. 2